Potential hazards of adding nonsteroidal anti-inflammatory drugs to antithrombotic therapy after myocardial infarction: Time for more than a gut check

JAMA - Journal of the American Medical Association

Volumn 313, Issue 8, 2015, Pages 801-802

  Campbell, Charles L ^a   Moliterno, David J ^b  

^a UNIVERSITY OF TENNESSEE AT CHATTANOOGA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIVITAMIN K; CELECOXIB; CLOPIDOGREL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; PROTON PUMP INHIBITOR; FIBRINOLYTIC AGENT;

ACUTE CORONARY SYNDROME; ANALGESIC ACTIVITY; ANTIPYRETIC ACTIVITY; ARTERY EMBOLISM; BLEEDING; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DRUG MEGADOSE; DUODENUM ULCER; EDITORIAL; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; MONOTHERAPY; OBSERVATIONAL STUDY; OSTEOARTHRITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SECONDARY PREVENTION; STOMACH IRRITATION; STOMACH ULCER; CHEMICALLY INDUCED; FEMALE; MALE; MYOCARDIAL INFARCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HUMANS; MALE; MYOCARDIAL INFARCTION;

EID: 84923308235     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2015.0567     Document Type: Editorial

References (10)

1. Harirforoosh S, AsgharW, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821-847.
2. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954-959.
3. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? meta-analysis of randomised trials. BMJ. 2006;332(7553):1302-1308.
4. Trelle S, Reichenbach S,Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.
5. Amsterdam EA,Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64 (24):e139-e228.
6. Schjerning Olsen A-M, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy aftermyocardial infarction. JAMA. doi:10.1001/jama.2015.0809.
7. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation. 2006;114(8):774-782.
8. Scheiman JM. The use of proton pump inhibitors in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 2013;15(suppl 3):S5.
9. Bhatt DL, Cryer BL, Contant CF, et al COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-1917.
10. Becker MC,Wang TH, Wisniewski L, et al PRECISION Investigators. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009;157(4): 606-612.